Vivos Therapeutics (VVOS) Invested Capital (2019 - 2026)

Vivos Therapeutics (VVOS) posted quarterly Invested Capital of $7.3 million for Q1 2026, up 4244.64% quarter-over-quarter from $168000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Invested Capital (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has reported Invested Capital for 5 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Invested Capital changed N/A year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $8.0 million (changed N/A YoY), while the FY2025 annual figure was $168000.0, changed N/A from the prior year.
Invested Capital grew to $7.3 million in Q1 2026 per VVOS's latest filing, from $168000.0 in the prior quarter.
Across five years, Invested Capital topped out at $7.3 million in Q1 2026 and bottomed at $157000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	3.01 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	750.00 Mn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	1.79 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	1.71 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	-
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	2.00 Mn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	1.34 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	243.40 Mn
10	Vivos Therapeutics	4.94 Mn	3.14 Mn	2.95 Mn	7.77 Mn

Download Data